A Review of Coronavirus Disease Covid-19

International Journal of Advanced Research in Science Communication and Technology, Journal Year: 2021, Volume and Issue: unknown, P. 104 - 115

Published: Sept. 16, 2021

Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids. Opportunistic fungal infections are of concern in such patients. While COVID-19 associated pulmonary aspergillosis increasingly recognized, mucormycosis rare. We describe a case probable 55-year-old man diabetes, end-stage kidney disease, and COVID-19. The index was diagnosed 21 days following admission for severe He received 5 g liposomal amphotericin B discharged after 54 from the hospital. also performed systematic review literature identified seven additional cases (CAM). Of eight included our review, diabetes mellitus most common risk factor. Three subjects had no factor other than glucocorticoids Mucormycosis usually developed 10–14 hospitalization. All except died. In two subjects, CAM postmortem. an uncommon but serious infection that complicates course Subjects multiple factors may be at higher developing mucormycosis. Concurrent glucocorticoid therapy probably heightens A high suspicion aggressive management required to improve outcomes.

Language: Английский

---

Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations

Japanese Journal of Ophthalmology, Journal Year: 2021, Volume and Issue: 65(4), P. 515 - 525

Published: May 31, 2021

Language: Английский

---

Invasive Fungal Sinusitis in Post COVID‐19 Patients: A New Clinical Entity

The Laryngoscope, Journal Year: 2021, Volume and Issue: 131(12), P. 2652 - 2658

Published: May 19, 2021

Occurrence of invasive fungal respiratory superinfections in patients with COVID-19 has gained increasing attention the latest studies. Yet, description acute sinusitis its management those is still scarce. This study aims to describe this recently clinical entity relation patients.Longitudinal prospective study.Prospective longitudinal included diagnosed rhinosinusitis after a recent infection. Antifungal agents given amphotericin B, voriconazole, and/or posaconazole. Surgical treatment was restricted PCR negative results for COVID-19. Endoscopic, open, and combined approaches were utilized eradicate Follow-up survived maintained regularly first postoperative month.A total 36 mean age 52.92 ± 11.30 years old included. Most common associated disease diabetes mellitus (27.8%). Mycological analysis revealed infection Mucor Aspergillus species 77.8% 30.6% patients, respectively. Sino-nasal, orbital, cerebral, palatine involvement found 100%, 80.6%, 27.8%, 33.3% The most reported symptoms signs are facial pain (75%), numbness (66.7%), ophthalmoplegia, visual loss (63.9%). All treated simultaneously by surgical debridement antifungal medications except two PCR-positive swab These received therapy alone. Overall survival rate 63.89% (23/36).Clinical suspicion among early essential better outcomes higher survival.4 Laryngoscope, 131:2652-2658, 2021.

Language: Английский

---

Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy

Journal of Fungi, Journal Year: 2021, Volume and Issue: 7(2), P. 88 - 88

Published: Jan. 27, 2021

Viral infections can cause acute respiratory distress syndrome (ARDS), consequently leading to susceptibility for secondary pulmonary infections. Over the past few weeks, a number of studies have reported on aspergillosis complicating severe COVID-19. We report case 53-year old male patient with myeloid leukemia (AML) who suffered from COVID-19 ARDS and was diagnosed postmortem mucormycosis.

Language: Английский

---

Coronavirus Disease 2019–Associated Invasive Fungal Infection

Open Forum Infectious Diseases, Journal Year: 2021, Volume and Issue: 8(12)

Published: Nov. 16, 2021

Coronavirus disease 2019 (COVID-19) can become complicated by secondary invasive fungal infections (IFIs), stemming primarily from severe lung damage and immunologic deficits associated with the virus or immunomodulatory therapy. Other risk factors include poorly controlled diabetes, structural and/or other comorbidities, colonization. Opportunistic IFI following respiratory viral illness has been increasingly recognized, most notably influenza. There have many reports of COVID-19, initially predominated pulmonary aspergillosis, but recent emergence mucormycosis, candidiasis, endemic mycoses. These be challenging to diagnose are poor outcomes. The reported incidence varied, often related heterogeneity in patient populations, surveillance protocols, definitions used for classification infections. Herein, we review complicating COVID-19 address knowledge gaps epidemiology, diagnosis, management COVID-19-associated

Language: Английский

---